drugset / Trial / NCT00203879

Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma

NCT00203879

Phase 2 Completed 19 enrolled University of Chicago
RandomizedParallel-groupOpen-labelTreatment

Summary

Purpose of investigation: Primary hypotheses: Immunization of patients with 4 melanoma antigen peptides will induce augmented specific IFN-y-producing CD8+ T cells against all 4 antigens simultaneously. Immunization with 4 melanoma antigen peptides will increase the response rate from 10% to 30%. Administration of low-dose IL-2 following each vaccine will result in a greater than 3-fold increase in specific T cells compared to no IL-2. Secondary hypotheses: Immunization will clear the blood of detectable circulating melanoma cells. Tumors that grow despite induction of melanoma antigen-specific T cells may lack expression of antigens, class I MHC, or the TAP peptide transporter, or may fail to show increased expression of mRNA for IFN-y or perforin. Tumors that resist vaccination may express a different array of genes than those that are susceptible to vaccination.

Timeline

Start
2002-02
Primary completion
2006-05
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC Unknown Subcutaneous
Subject aldesleukin Protein / enzyme biologic Subcutaneous
Background INTERLEUKIN-12 HUMAN RECOMBINANT Unknown 4 ug Subcutaneous

Indications